Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...
Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. antico ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...
Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit ...
Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE).
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at ...
Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in ...
Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results